PharmaJet to present latest Research Results at World Vaccine Congress

Tuesday, March 27, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

Needle-free devices delivering superior immunogenicity

GOLDEN, Colo., March 27, 2018 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection

technology, today announced plans to present their latest research results at the World Vaccine Congress on April 5, in Washington DC at the Renaissance Washington DC Downtown Hotel.  The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

Immunotherapy using novel pharmaceuticals has led to new emerging vaccines and therapeutics, based on platforms including DNA, RNA, antibodies, personalized medicine and others.  For these nucleic acid-based vaccines to work, the vaccine must get directly into the cells, necessitating an improved delivery method. Multiple studies have shown that the PharmaJet Needle-free Injectors augment vaccine response, possibly by increased dispersion of injectate or through tissue disruption, enabling a more efficient uptake of vaccine and increased immunogenicity.  These superior results have been replicated in several DNA and RNA vaccine clinical trials for zika virus, cancer, smallpox and rabies.   Collaborators including the NIH, Invectys, Vaccibody, CureVac and others are using this technology to move from pre-clinical studies into human trials.

"We now have over 40 novel pharmaceuticals, including DNA and RNA vaccines and therapeutics, using our devices in pre-clinical and clinical studies worldwide," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc. "The data has been overwhelmingly positive for clinical efficacy using our devices1."

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Data on file

About PharmaJetBased in Golden, Colorado, PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.  The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016.  The PharmaJet Needle-free Injectors are safe, fast and easy-to-use.  They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com.

CONTACT: Nancy LillieNancy.Lillie@pharmajet.com1-888-900-4321 Option 3

 

Cision View original content:http://www.prnewswire.com/news-releases/pharmajet-to-present-latest-research-results-at-world-vaccine-congress-300618856.html

SOURCE PharmaJet

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store